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Disposition of uric acid upon administration of ofloxacin (O) 
alone and in combination with other anti-tuberculosis drugs, 
rifampicin (R), isoniazid (H) and pyrazinamide (Z) was studied. 
Twelve male healthy volunteers were investigated on four 
different occasions with the four drugs alone or in combinations. 
A partially balanced incomplete block design was adopted and the 
subjects were randomly allocated to each group. Uric acid 
concentration in urine samples excreted over 0-8 hr, were 
determined after coding the samples. There was significant 
decrease in the group receiving Z when compared to other groups. 
Though there was a decrease in uric acid excretion in the group 
receiving O, it was not statistically significant. Rifampicin and H 
seem to increase the uric acid excretion. The incidence of 
arthralgia was mainly due to Z and not due to either O or other 
drugs in the treatment of pulmonary tuberculosis. 
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It is well known that uric acid is derived from purines 
which are primarily formed from the normal 
breakdown of body tissue and secondarily from 
dietary sources. In the human, approximately 2/3 of 
the total uric acid production is excreted via kidney. It 
is clearly established that uric acid is freely filterable 
by the glomerulus, re-absorbed almost completely by 
the proximal tubules and secreted by the tubules. A 
blockage of tubular secretion results in uricosuria. 
Urate excretion is a complex process and a familiarity 
with the complexities of uric acid excretion is 
essential, since drugs can alter these processes. 
Administration of pyrazinamide (Z) in the 
chemotherapy of tuberculosis (TB) results in 
arthralgia1. Pyrazinamide suppresses the urinary 
excretion of uric acid by inhibiting tubular secretion, 
thereby retaining uric acid. The retained uric acid as 
sodium urate is probably deposited in the joints, 
leading to arthralgia. 
There are several reports that uric acid excretion is 
suppressed in TB patients receiving Z containing 
regimen2. This results in arthralgia which is probably 
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due to hyperuricaemia caused by pyrazinoic acid, the 
primary metabolite of Z. When rifampicin (R) is 
administered together with Z, the incidence of 
arthralgia is reduced3. 
Ofloxacin (O), a synthetic carboxy fluoroquinolone, 
is a valuable addition to the existing chemotherapy of 
pulmonary tuberculosis. In vitro studies demonstrate 
the bactericidal activity of O which suggests that it is 
the most useful drug in the early stages of treatment 
and prevents the emergence of resistance to other 
drugs4. Anti-tuberculosis (TB) regimens of 4 or 5 
months duration that contain O and other anti-TB drugs 
achieve more than 95% efficacy with no increased 
incidence of adverse reactions and minimal relapses, 
permitting shortening of duration5. 
Very little information is available on the disposition 
of uric acid upon administration of O together with 
other anti-TB drugs. Therefore, it was aimed to study 
the clinical implications of uric acid disposition when 
O was administered alone and in combination with 
other anti-TB drugs. 
Treatment and sample collection -Twelve male 
healthy volunteers with the mean age of 23 years (19- 
27 years) and the mean body weight of 56 kg (45-69 
kg) are included in this study and all the volunteers 
gave written informed consent prior to participation in 
the study. The volunteers are healthy as determined by 
comprehensive medical history, physical examinations 
and laboratory profiles. None of the subjects was 
taking medications within one week or during the study 
and also are non-alcoholics. None of the subjects had a 
history or current evidence of significant renal, hepatic 
or haematological disease. The Institutional Ethic 
Committee clearance was obtained prior to start of the 
study. 
Each volunteer was investigated on four different 
occasions with the four drugs, viz., O (Dee Pharma 
Ltd.), R (Asojsof Caps. Pvt. Ltd.), Z (Lupin 
Laboratories) and H (Pfizer), either alone or in 
combinations, viz., O, R, H, Z, OR, OH, OZ and 
ORHZ with an interval of atleast one week between 
occasions. A partially balanced incomplete block 
design was adopted where the drugs were administered 
to the volunteers at random. 
The dosages of the drugs administered were 
approximately 10 mg/kg body weight for R, 35 mg/kg 
for Z and 15 mg/kg body weight for O and H. 
The drugs were administered on an empty stomach 
and urine sample excreted over the period of 0-8 hr 
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were collected. The volume of the urine excreted was 
measured and the aliquots stored at -20°C until assay 
was performed. 
Uric acid concentration in urine were determined by 
the phosphotungstate reduction method6 after coding 
the samples. Uric acid in urine reduces an alkaline 
phosphotungstase solution to a tungsten blue. The 
intensity of the colour is proportional to the 
concentration of uric acid present in the urine and is 
measured photometrically against the standard. 
Creatinine estimation was also carried out by Jaffe's 
method7 to ascertain the completeness of urine 
collection. 
Urinary excretion of uric acid when O was given 
alone and in combination was estimated in the samples 
collected over the periods 0-8 hr. The mean urinary 
excretion of uric acid following administration of O, R, 
H, Z alone and in combinations have been presented in 
Fig. 1. The uric acid excretion was significantly 
decreased in OZ group (65.4 mg/dl), compared to O 
alone (196.5 mg/dl). When OZ group was compared 
with Z alone (53.7 mg/dl), there was a decrease in the 
urinary excretion of uric acid and it was not statistically 
significant. 
Urinary excretion of uric acid was compared 
between the groups O alone and ORHZ (1 89.6 mg/dl) 
where the difference was not statistically significant. 
On the other hand, when Z alone group was compared 
with ORHZ, there was significant increase in uric acid 
excretion. 
OR group (275.1 mg/dl) when compared with R 
alone (279.6 mg/dl), the urinary excretion of uric acid 
remained the same. Similarly, OH group (372.8 
mg/dl) was compared with H alone (275.2 mg/dl), and 
observed no significant difference in the uric acid 
value. 
Fig. 1 -Urinary excretion of uric acid following administration of 
O, R, H and Z alone and in combinations. The vertical bars denote 
standard deviation. [*Significant at P <0.05 when compared to O 
alone] 
It was evident from the findings that the 
suppression of urinary excretion of uric acid was 
mainly due to Z. There was significant decrease in the 
mean rate of urinary excretion of uric acid when OZ 
was compared with O group. Pyrazinamide is 
metabolized to pyrazinoic acid (PZC) by hepatic 
microsomal pyrazinamide deamida8,9 and the latter 
suppresses urinary excretion of uric acid by inhibiting 
acid in Z and OZ group remained unchanged and it 
was not statistically significant proving that O does 
not decrease the uric acid excretion, when combined 
with Z. Therefore, Z played a major role in the 
urinary excretion of uric acid which was evident from 
uric acid retention. 
Studies conducted by Sarma et al.2 have shown that 
Z caused a significant decrease in the renal excretion 
of uric acid. Rifampicin enhanced the renal excretion 
of uric acid both in the presence and absence of Z. 
This effect could lead to a decrease in the deposition 
of uric acid in joints and consequently to a lower 
incidence of arthralgia. 
Present results showed that O alone when 
compared with ORHZ group, there was no significant 
difference in the urinary excretion of uric acid 
whereas when Z alone was compared with ORHZ 
group, the uric acid excretion was significantly 
elevated. Rifampicin and H seemed to increase the 
uric acid excretion. In pulmonary TB patients, treated 
with all the four drugs (O, R, H and Z), the incidence 
of arthralgia was mainly due to Z and not due to O or 
other drugs. 
A controlled clinical trial of 3, 4 and 5 months 
regimens containing O for the treatment of patients 
with sputum positive pulmonary TB in South India, 
was conducted at the centre, with an objective of 
shortening the duration of treatment5. The results have 
shown that 4 and 5 months regimens using O as one 
of the drugs in the initial-intensive phase, can be as 
effective as the currently widely recommended 
regimens in patients with drug sensitive bacilli and 
have great promise for application in TB control in 
the future. In these patients, the serum uric acid values 
were monitored during the course of treatment. It was 
found that the serum uric acid levels were elevated 
only during the first phase of treatment which 
contained all the four drugs (O, H, R and Z) and it 
returned to normal during the second phase of 
treatment which contained only R and H (unpublished 
data). Therefore, the elevation of serum uric acid must 
be due to Z or O. Studies have shown that the 
incidence of arthralgia is due to Z1. Since O is also 
its tubular secretion 2,10,16 . Urinary excretion of uric 
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administered in the multiple regimen therapy, the 
question arises whether O also plays a role in the 
suppression of uric acid excretion. 
Toxicologic evaluation of O has shown that it is 
well tolerated within reasonable multiples of the 
intended clinical dose17. Safety profiles of O are 
evaluated on the basis of adverse reactions18. Adverse 
reactions are not serious and usually rapidly 
reversible. Present results clearly demonstrated that 
the administration of O did not play a role in the 
suppression of urinary excretion of uric acid. The data 
presented provides a clear evidence that urinary 
excretion of uric acid was significantly decreased 
upon administration with Z, thereby leading to 
arthralgia. Therefore, O could be a valuable 
therapeutic agent in the treatment of pulmonary TB 
besides a variety of indications. The shorter duration 
of treatment with O containing regimens would 
hopefully improve patient adherence. 
The authors wish to thank the volunteers for their 
willingness to participate in this study and Mr B 
Doraiswamy for secretarial assistance. 
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